Windtree Therapeutics, dubbed the "BNB MicroStrategy" company, received notification from NASDAQ on August 19, 2025, that its common stock will be delisted from the NASDAQ Capital Market on August 21 due to failure to meet the minimum closing price maintenance standards under Rule 5550(a)(2). The stock will subsequently transfer to OTC market trading.
Previously, the company had announced plans to raise up to $520 million through equity financing, with 99% of the proceeds intended for purchasing BNB.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.